Scandion Oncology A/S (SCOL.ST)
SEK 0.01
(3.85%)
SEK 0.01
(3.85%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -50.66 Million | -69.44 Million | -49.79 Million | -17.45 Million | -9.95 Million | -13.27 Million |
| Net Income | -44.7 Million | -82.2 Million | -57.21 Million | -22.88 Million | -15.39 Million | -9.93 Million |
| Depreciation & Amortization | 969 Thousand | 882 Thousand | 604 Thousand | 36 Thousand | -7142.00 | - |
| Deferred income taxes | - | - | -379 Thousand | -865.00 | - | - |
| Stock-based compensation | - | - | 379 Thousand | 865 Thousand | - | - |
| Change in working capital | -12.43 Million | 6.37 Million | 2.06 Million | 5.4 Million | 5.59 Million | -3.31 Million |
| Other non-cash items | 5.49 Million | 5.5 Million | 4.74 Million | -4000.00 | -155.72 Thousand | -23.32 Thousand |
| Investing Cash Flow | 288 Thousand | -389 Thousand | -485 Thousand | -46 Thousand | -238.27 Thousand | - |
| Investments in PPE | - | -414 Thousand | -318 Thousand | -46 Thousand | -245 Thousand | - |
| Acquisitions | - | - | 167.00 | - | - | - |
| Investment purchases | - | - | -258 Thousand | - | -238.27 Thousand | - |
| Sales/Maturities of investments | - | 25 Thousand | 91 Thousand | - | - | - |
| Other Investing Activities | 288 Thousand | 25.00 | -167.00 | - | -245.00 | - |
| Financing Cash Flow | -705 Thousand | 41.72 Million | 150.17 Million | 7.89 Million | 17.95 Million | 19.29 Million |
| Debt repayment | -705.00 | -760.00 | -511.00 | -226.00 | -1000.00 | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 53.54 Million | 150.69 Million | 7.89 Million | 17.95 Million | 19.29 Million |
| Other Financing Activities | -705 Thousand | -11.81 Million | -510.48 Thousand | -1774.00 | 17.95 Million | 19.29 Million |
| Accounts receivables | 2106.00 | -657.00 | -1485.00 | -779.00 | 5036.00 | -3.8 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -12.43 Million | 6.37 Million | 2.06 Million | 5.4 Million | 5.59 Million | - |
| Cash at beginning of period | 77.6 Million | 105.71 Million | 5.81 Million | 15.42 Million | 7.66 Million | 1.63 Million |
| Cash at end of period | 26.52 Million | 77.6 Million | 105.71 Million | 5.81 Million | 15.42 Million | 7.66 Million |
| Capital Expenditure | - | -414 Thousand | -318 Thousand | -46 Thousand | -245 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -51.08 Million | -28.1 Million | 99.89 Million | -9.6 Million | 7.75 Million | 6.02 Million |
| Free Cash Flow | -50.66 Million | -69.85 Million | -50.11 Million | -17.49 Million | -10.2 Million | -13.27 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.13 Million | -9.9 Million | -44.7 Million | -10.98 Million | -10.55 Million | -11.25 Million |
| Depreciation & Amortization | 110 Thousand | 110 Thousand | 969 Thousand | 259 Thousand | 220 Thousand | 245 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 5.13 Million | 235 Thousand | -12.43 Million | -4.69 Million | 1.09 Million | -3.27 Million |
| Other non-cash items | -225 Thousand | -193 Thousand | 5.49 Million | 5.49 Million | -355 Thousand | -66 Thousand |
| Investing Cash Flow | - | 88 Thousand | 288 Thousand | 247 Thousand | 41 Thousand | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 88 Thousand | 288 Thousand | 247 Thousand | 41 Thousand | - |
| Financing Cash Flow | 13.88 Million | -90 Thousand | -705 Thousand | -132 Thousand | -182 Thousand | -196 Thousand |
| Debt repayment | -89 Thousand | -90 Thousand | -705.00 | -132.00 | -182.00 | -196.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 19.89 Million | - | - | - | - | - |
| Other Financing Activities | 13.97 Million | - | - | - | - | -195.8 Thousand |
| Accounts receivables | - | - | 2106.00 | 2106.00 | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5.13 Million | 235 Thousand | -12.43 Million | -4.69 Million | 1.09 Million | -3.27 Million |
| Cash at beginning of period | 16.95 Million | 26.52 Million | 77.6 Million | 36.33 Million | 45.7 Million | 60.18 Million |
| Cash at end of period | 26.95 Million | 16.95 Million | 26.52 Million | 26.52 Million | 36.33 Million | 45.7 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | 4000.00 | - |
| Net cash flow / Change in cash | 9.99 Million | -9.56 Million | -51.08 Million | -9.81 Million | -9.37 Million | -14.47 Million |
| Free Cash Flow | -3.89 Million | -9.56 Million | -50.66 Million | -9.92 Million | -9.23 Million | -14.28 Million |
2722
KLBN3
3RB
1140
002810
TAWNF